NYXOAH S A Stock Price, News & Analysis

Nyxoah SA announced receiving a transparency notification from Vestal Point Capital regarding changes in voting rights holdings. According to the notification dated May 27, 2025, Vestal Point Capital reduced its position to 1,809,843 voting rights, representing 4.84% of total voting rights (37,427,265) as of May 21, 2025. This represents a significant decrease from their previous holding of 3,000,688 voting rights. Vestal Point Capital, LP is controlled by Vestal Point Capital, LLC as general partner, which is in turn controlled by Ryan Wilder as managing member. The notification was triggered by crossing below the 5% threshold.

Nyxoah SA (NYXH), a medical technology company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York from June 3-5, 2025. CEO Olivier Taelman will deliver a corporate presentation on June 4, 2025, at 4:55pm ET. The presentation will be accessible via webcast on Nyxoah's Investor Relations website's Events section. The company will also be available for one-on-one meetings with institutional investors during the conference.

Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its share capital and voting rights structure as of May 23, 2025. The company's share capital stands at EUR 6,430,026.16. The total number of securities carrying voting rights is 37,429,265 ordinary shares, with an equal number of voting rights. Additionally, there are 2,854,068 subscription rights to securities not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.

Nyxoah reported its Q1 2025 financial results and provided an update on its FDA approval progress for the Genio® system, a neuromodulation treatment for Obstructive Sleep Apnea (OSA). The company received an FDA Approvable Letter and successfully completed validation requirements, with only the final site inspection pending. Q1 2025 financial highlights include: - Revenue of €1.1M (down from €1.2M in Q1 2024) - Operating loss increased to €20.6M (vs €12.2M in Q1 2024) - Cash position of €63.0M as of March 31, 2025 - Gross margin of 61.8% The company expects potential FDA approval in Q2 2025, having already completed most regulatory requirements. The increased operating loss reflects higher R&D expenses (€9.0M) and selling, general and administrative costs (€12.4M) as Nyxoah prepares for U.S. commercialization.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has received a transparency notification from FMR LLC regarding changes in shareholding. FMR LLC and its controlled undertakings now hold 1,111,240 voting rights (2.97% of total voting rights) as of April 29, 2025, consisting of 987,776 voting rights linked to securities and 123,464 equivalent financial instruments. This represents a downward crossing below the 3% threshold.

The voting rights are distributed among Fidelity Management & Research Company LLC (2.07%), FIAM LLC (0.00%), and FMR Investment Management UK Limited (0.57%). The notification includes a stock loan as an equivalent financial instrument representing 0.33% of voting rights.

Nyxoah SA (NYXH) has announced its annual and extraordinary shareholders' meetings to be held on June 11, 2025, at 2:00 p.m. CET. The meetings will take place at the company's headquarters in Mont-Saint-Guibert, Belgium. Key agenda items include: Annual Meeting Highlights: - Review and approval of 2024 financial statements - Discharge of directors and statutory auditor - Approval of amended remuneration policy - Authorization for increased severance packages for CEO and CFO (up to 18 months) in case of change of control - Reappointment of multiple directors including Robelga SRL, Jürgen Hambrecht, and Kevin Rakin - Reappointment of Ernst & Young as statutory auditor Extraordinary Meeting: - Proposed amendment to Article 13 of articles of association regarding director nomination rights for shareholders holding ≥5% of shares for 3+ years

Nyxoah (Nasdaq/Euronext: NYXH), a company focused on developing innovative neuromodulation treatments for Obstructive Sleep Apnea (OSA), has scheduled its Q1 2025 financial results release for May 14, 2025. The company will host a conference call with management on the same day at 2:00pm CET / 8:00am ET.

Investors and analysts can access the earnings call through the company's Investor Relations webpage or via webcast link. Those planning to ask questions during the call should register at least 10 minutes before the start time using a separate registration link. A replay of the webcast will be available shortly after the call concludes.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has announced a conditional issuance of up to 5 million ordinary shares through its existing at-the-market (ATM) equity offering programs. This brings the total potential ATM shares to 5,662,694, including 662,694 shares still available from a previous conditional issuance decided on December 22, 2022.

The ATM shares will be sold at prevailing USD market prices on the Nasdaq Global Market at the time of sale, in accordance with the existing sales agreement from December 22, 2022.

Nyxoah (NYXH) announced an update regarding the FDA approval process for its Genio system, a neuromodulation treatment for Obstructive Sleep Apnea (OSA). The FDA issued an Approvable Letter on March 26, 2025, indicating that the PMA application substantially meets federal requirements.

The FDA has accepted all clinical data demonstrating Genio's safety and effectiveness. Only one item remains before final approval: the validation of a process used with a component at the U.S. manufacturing site. The company expects to complete this validation and potentially receive full PMA approval in the second quarter of 2025.